AP
EGRX

AHL Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

AHL Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,316
Closed -$472K – 844
2015
Q4 		$472K Buy
+5,316
New +$420K 0.04% 484

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

AHL Partners's EGRX Position: Q1 2016 in Review

AHL Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2016, closing a stake of 5,316 shares — an estimated $472K sold.

AHL Partners first reported a position in EGRX in Q4 2015 and held it in 1 quarter. The position peaked at $472K in Q4 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q1 2016.

  • AHL Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • AHL Partners sold 5,316 Eagle Pharmaceuticals, Inc. shares in Q1 2016, an estimated $472K.
  • AHL Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • AHL Partners's Eagle Pharmaceuticals, Inc. position peaked at $472K in Q4 2015.
  • 119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2016.

Based on AHL Partners's 13F filing for Q1 2016, filed 16 May 2016.